What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Her scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Neoadjuvant therapy and Cancer.
Her Breast cancer research is multidisciplinary, incorporating elements of Surgery, Radiation therapy, Gynecology and Hazard ratio.
In general Internal medicine, her work in Chemotherapy, Trastuzumab, Taxane and Cyclophosphamide is often linked to Carboplatin linking many areas of study.
Her Oncology study combines topics from a wide range of disciplines, such as Clinical trial, Pathology, Anthracycline, Capecitabine and Tumor-infiltrating lymphocytes.
Her studies in Neoadjuvant therapy integrate themes in fields like Bevacizumab, Clinical research, Adjuvant and Docetaxel.
Sibylle Loibl has included themes like Cancer research and Carcinoma in her Cancer study.
Her most cited work include:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (1756 citations)
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes (1376 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer.
Her study in Internal medicine focuses on Neoadjuvant therapy, Trastuzumab, Clinical trial, Taxane and Triple-negative breast cancer.
Her research in Breast cancer intersects with topics in Surgery, Pathology, Gynecology, Docetaxel and Hazard ratio.
In her research, Paclitaxel is intimately related to Epirubicin, which falls under the overarching field of Oncology.
Her Chemotherapy study incorporates themes from Gastroenterology, Pathological, Capecitabine and Early breast cancer.
Her Cancer study frequently draws connections to other fields, such as Cancer research.
She most often published in these fields:
- Internal medicine (73.51%)
- Breast cancer (70.20%)
- Oncology (66.00%)
What were the highlights of her more recent work (between 2019-2021)?
- Breast cancer (70.20%)
- Internal medicine (73.51%)
- Oncology (66.00%)
In recent papers she was focusing on the following fields of study:
Sibylle Loibl mostly deals with Breast cancer, Internal medicine, Oncology, Chemotherapy and Cancer.
Her work in the fields of Breast cancer, such as Neoadjuvant therapy and Trastuzumab, overlaps with other areas such as Carboplatin.
Sibylle Loibl regularly links together related areas like Gastroenterology in her Internal medicine studies.
Her research investigates the link between Oncology and topics such as Early breast cancer that cross with problems in Dose-dense chemotherapy.
Sibylle Loibl studied Chemotherapy and Taxane that intersect with Anthracycline and Neutropenia.
Her research in Cancer tackles topics such as Placebo which are related to areas like Anastrozole.
Between 2019 and 2021, her most popular works were:
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (196 citations)
- Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial (52 citations)
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. (50 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Her primary scientific interests are in Internal medicine, Breast cancer, Oncology, Neoadjuvant therapy and Chemotherapy.
Her study involves Randomized controlled trial, Trastuzumab, Cancer, Predictive biomarker and Stromal tumor, a branch of Internal medicine.
Her Breast cancer research includes themes of Clinical trial, Phases of clinical research, Adverse effect and Hazard ratio.
Her work carried out in the field of Oncology brings together such families of science as Regimen, Metastatic breast cancer, Palbociclib, Biomarker and Triple-negative breast cancer.
Her Neoadjuvant therapy research includes elements of Gastroenterology, Multivariate analysis, Pathological and Cumulative incidence.
Her Chemotherapy study combines topics from a wide range of disciplines, such as Guideline, Endocrine therapy, Targeted therapy, Recurrence risk and Pooled analysis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
